Sign up Australia
Proactive Investors - Run By Investors For Investors

Analytica expands clinical indication for its unique pelvic floor exercise technology

PeriCoach system is now indicated for urinary incontinence, sexual wellness and pelvic organ prolapse.
PeriCoach System demostration
No other system on the market has this capability

Analytica Limited (ASX:ALT) has received clearance from the Australian Therapeutic Goods Administration for the expanded clinical indication for its PeriCoach System to assist in the conservative treatment of Pelvic Organ Prolapse (POP).

The PeriCoach system with its patent protected force sensing technology assists women to properly perform pelvic floor exercises.

The expanded clinical indication for PeriCoach now includes targeted resolution of symptoms for mild to moderate POP, urinary incontinence and sexual wellness.

Pelvic organ prolapse is a common and serious condition

Data suggests that 50% of women that have given birth have some degree of POP and half of women over 50 complain of prolapse symptoms.

Estimates state women have a lifetime risk of up to 12% of undergoing a surgical intervention, with a re-operation rate of nearly 20%.

Each surgical intervention in the U.S. is estimated to cost between USD$10,000- USD$20,000.

As the population continues to age and awareness of the condition grows, it is projected that the number of women with POP will increase up to 46%.

Potential sale of the technology to a multinational

Analytica chairman Dr Michael Monsour said: “This clearance from the TGA is significant in that the PeriCoach system is indicated for the most common conditions stemming from a weak pelvic floor: urinary incontinence, sexual wellness, and pelvic organ prolapse.

“No other system on the market has this capability.

“This additional capability adds substantial value and progresses the sale of the company and PeriCoach system to a multinational”.

View full ALT profile View Profile

Analytica Ltd Timeline

Newswire
January 18 2016
Newswire
October 08 2014
Newswire
September 29 2014

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
scientist with vial
August 09 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use